[Response to the rebuttal by Mikulak et al.]{.ul}

In response to the rebuttal by Mikulak et al.*,* we wish to extend the discussion to this important topic of "innateness" in Vδ2^pos^ T cells. The papers cited indeed refer to adaptation of the Vγ9^neg^/Vδ2^pos^. However, this is in the context of CMV infection, not CMV history (aged individuals), which was the focus of our study \[[@bb0010]\]. A limitation of our study is the unknown time of primo-infection by CMV. Also, our study did not look into the Vγ9^neg^ subsets, but overall our findings add evidence that Vδ2^pos^ T cells have a more innate profile than their Vδ1^pos^ counterpart. Based on Davey *et al*., \[[@bb0005]\] the proportion of Vγ9^neg^/Vδ2^pos^ is about 2%. Thus, we can assume that the subset we are observing in our study was largely Vγ9^pos^/Vδ2^pos^. Our observation that bulk Vδ2^pos^ is not driven to the stage of senescence by CMV history and age converges with several other studies albeit they used other differentiation markers (i.e. CD27, CD28) \[[@bb0015],[@bb0020]\]. Moreover, we do not exclude that response to cytokines may differ based on the naïve/memory markers as shown using IL-15, and epigenetic studies may better explain it in γδ T cell subpopulations, as shown for αβ T cells \[[@bb0025]\]. Finally, previous studies cited by Mikulak et al. have shown the age-dependent alteration in Vδ2^pos^ subsets to be absent in females and naïve/memory distribution to vary in lymph nodes, other organs and inflamed tissue. Taking into consideration the physiological adaptations during aging, and the presence of low-grade inflammation, the study of Vδ2^pos^ T cells in other clinical contexts will be required to fully decipher their homeostasis.
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